Drug Search Results
More Filters [+]

Neramexane

Alternative Names: neramexane
Latest Update: 2023-08-02
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: NMDA Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merz
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Neramexane

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Tinnitus|Alzheimer Disease

Phase 2: Tinnitus|Nystagmus, Pathologic|Multiple Sclerosis|Nystagmus, Congenital|Cancer Pain|Chronic Pain|Acute Pain|Pain, Postoperative

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2011-004998-83

P2

Completed

Unknown

2013-07-09

OLLTT

P3

Terminated

Tinnitus

2011-12-01

2008-001432-13

P3

Terminated

Tinnitus

2011-10-12

2009-011246-25

P3

Completed

Tinnitus

2011-06-03

Recent News Events